SCHEMBL25609752

SCHEMBL25609752

Nc1nc(Nc2ccc(F)c(F)c2)sc1C(=O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.58
KMT2A Q03164 7/20 0.58
MAPT P10636 6/20 0.58
CDK5 Q00535 4/20 0.58
CDK5R1 Q15078 4/20 0.58
LMNA P02545 2/20 0.58
CCNA2 P20248 6/20 0.58
CDK2 P24941 6/20 0.58
NPC1 O15118 5/20 0.56
RAB9A P51151 3/20 0.55
CLK1 P49759 1/20 0.55
TP53 P04637 1/20 0.55
GSK3A P49840 1/20 0.54
GSK3B P49841 1/20 0.54
MAPK14 Q16539 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
ZAP70 P43403 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
TUBB8B A6NNZ2 1/20 0.51
TUBB4A P04350 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25609754 0.92 MAPT (0.56) MEN1KMT2AMAPTCDK5CDK5R1
SCHEMBL31415130 0.92 MAPT (0.56) MEN1KMT2AMAPTCDK5CDK5R1
SCHEMBL25609676 0.90 CCNA2 (0.73) MEN1KMT2AMAPTCDK5CDK5R1
SCHEMBL25609823 0.88 CCNA2 (0.70) MEN1KMT2AMAPTCDK5CDK5R1
SCHEMBL20141868 0.88 CDK5 (0.64) MEN1KMT2AMAPTCDK5CDK5R1
SCHEMBL25609758 0.87 CCNA2 (0.56) MEN1KMT2AMAPTCDK5CDK5R1
SCHEMBL25609608 0.86 CCNA2 (0.75) MEN1KMT2AMAPTCDK5CDK5R1
SCHEMBL25609790 0.86 MEN1 (0.62) MEN1KMT2AMAPTCDK5CDK5R1
SCHEMBL25609636 0.84 MEN1 (0.79) MEN1KMT2AMAPTCDK5CDK5R1
SCHEMBL20142857 0.84 GSK3A (0.67) MEN1KMT2AMAPTCDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-04-23 US disclosed
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230139936-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-04 US disclosed
US-20230139936-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139936-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG MEN1 4344/4885KMT2A 1150/4885MAPT 3263/4885
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG MEN1 4344/4885KMT2A 1150/4885MAPT 3263/4885
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation DGKZ, DGKA, DGKG MEN1 4344/4885KMT2A 1150/4885MAPT 3263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.